US 12,291,504 B2
Small molecule inhibition of sulfotransferase SULT1A3
Alexander Deiters, Pittsburgh, PA (US); Kristie E. Darrah, Pittsburgh, PA (US); Mary Frances Cacace, Pittsburgh, PA (US); Ian Cook, Bronx, NY (US); Thomas Leyh, Bronx, NY (US); and Ting Wang, Bronx, NY (US)
Assigned to University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US); and Albert Einstein College of Medicine, Bronx, NY (US)
Appl. No. 17/299,733
Filed by University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US); and Albert Einstein College of Medicine, Bronx, NY (US)
PCT Filed Dec. 10, 2019, PCT No. PCT/US2019/065442
§ 371(c)(1), (2) Date Jun. 3, 2021,
PCT Pub. No. WO2020/123482, PCT Pub. Date Jun. 18, 2020.
Claims priority of provisional application 62/777,644, filed on Dec. 10, 2018.
Prior Publication US 2022/0024876 A1, Jan. 27, 2022
Int. Cl. C07D 219/06 (2006.01); C07D 215/04 (2006.01); C07D 215/48 (2006.01); C07D 249/06 (2006.01); C07D 401/04 (2006.01); C07D 471/04 (2006.01)
CPC C07D 219/06 (2013.01) [C07D 215/04 (2013.01); C07D 215/48 (2013.01); C07D 249/06 (2013.01); C07D 401/04 (2013.01); C07D 471/04 (2013.01)] 12 Claims
OG exemplary drawing
 
1. A compound having the structure of formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:

OG Complex Work Unit Chemistry
is a naphthalene or a quinoline;
X is selected from a bond and an optionally substituted alkyl or alkene;
Y is selected from —OR′, —CONR′2, —COOR′ and optionally substituted heteroaryl;
R′ is H or an optionally substituted alkyl;
Z is independently selected from H, optionally substituted alkyl, and —X-Y, or two Z together form an optionally substituted cycloalkyl, wherein when Z1 and Z2 are both H, then Y is heteroaryl, or wherein Z1 and Z2 are not both H;
a is 0 or an integer of 1-4; and
wherein the compound of formula (I) is selected from:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry